fluoxetine has been researched along with monocrotaline in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (33.33) | 29.6817 |
| 2010's | 10 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Brodde, OE; Leineweber, K; Seyfarth, T | 1 |
| Beilfuss, A; Brandt, K; Brodde, OE; Heinroth-Hoffmann, I; Leineweber, K; Pönicke, K; Wludyka, B | 1 |
| Adnot, S; Benferhat, R; Eddahibi, S; Guignabert, C; Hamon, M; Raffestin, B; Raoul, W; Rideau, D; Zadigue, P | 1 |
| Wang, HL; Zhai, FG; Zhang, XH | 1 |
| Huang, J; Mao, ZF; Wang, JY; Zhu, SP | 1 |
| Han, DD; Li, XQ; Wang, HL; Wang, HM; Yang, CG; Zhang, XH | 1 |
| Han, DD; Liu, M; Wang, HL; Wang, HM; Wang, Y; Zhang, XH | 1 |
| Wang, HL; Wang, Y; Zhang, XH | 1 |
| Han, DD; Liu, JR; Wang, HL; Wang, Y; Zhang, XH | 1 |
| Bai, Y; Liu, M; Sun, YX; Wang, HL; Wang, HM; Wang, Y; Zhang, XH | 1 |
| Abid, S; Adnot, S; Amsellem, V; Dubois-Randé, JL; Houssaini, A; Marcos, E; Mouraret, N; Rideau, D; Saker, M; Tissot, CM; Wan, F | 1 |
| Fujii, Y; Gray, EA; Pearson, JT; Schwenke, DO; Shirai, M; Sonobe, T; Tsuchimochi, H; Umetani, K; Yoshimoto, M | 1 |
| Bai, Y; Liu, M; Song, ZH; Wang, HL; Wang, HM; Wang, Y | 1 |
15 other study(ies) available for fluoxetine and monocrotaline
| Article | Year |
|---|---|
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Chamber-specific alterations of noradrenaline uptake (uptake(1)) in right ventricles of monocrotaline-treated rats.
Topics: Adrenergic Uptake Inhibitors; Animals; Binding, Competitive; Cocaine; Desipramine; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Fluoxetine; Heart Failure; Heart Ventricles; Hypertrophy; In Vitro Techniques; Male; Membranes; Monocrotaline; Norepinephrine; Piperazines; Rats; Rats, Wistar; Tritium | 2000 |
Ventricular hypertrophy plus neurohumoral activation is necessary to alter the cardiac beta-adrenoceptor system in experimental heart failure.
Topics: Animals; Binding, Competitive; Cell Membrane; Disease Models, Animal; Eye Proteins; Fluoxetine; G-Protein-Coupled Receptor Kinase 1; Heart Failure; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Male; Monocrotaline; Myocardium; Norepinephrine; Norepinephrine Plasma Membrane Transport Proteins; Organ Size; Protein Kinases; Rats; Rats, Wistar; Receptors, Adrenergic, beta; Receptors, Neurotransmitter; Rhodopsin; Symporters | 2002 |
Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats.
Topics: Animals; Cell Proliferation; Fluoxetine; Hypertension, Pulmonary; Lung; Monocrotaline; Muscle, Smooth, Vascular; Rats; Selective Serotonin Reuptake Inhibitors; Serotonin 5-HT1 Receptor Antagonists; Serotonin 5-HT2 Receptor Antagonists; Serotonin Plasma Membrane Transport Proteins; Up-Regulation | 2005 |
Fluoxetine protects against monocrotaline-induced pulmonary arterial hypertension: potential roles of induction of apoptosis and upregulation of Kv1.5 channels in rats.
Topics: Animals; Apoptosis; Blotting, Western; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Fluoxetine; Hypertension, Pulmonary; Kv1.5 Potassium Channel; Lung; Male; Monocrotaline; Muscle, Smooth, Vascular; Pulmonary Artery; Pulmonary Circulation; Rats; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Time Factors; Up-Regulation | 2009 |
Continuous fluoxetine administration prevents recurrence of pulmonary arterial hypertension and prolongs survival in rats.
Topics: Animals; Blotting, Western; Disease Models, Animal; Dose-Response Relationship, Drug; Fluoxetine; Hypertension, Pulmonary; Lung; Male; Monocrotaline; Pulmonary Artery; Pulmonary Circulation; Rats; Rats, Wistar; Secondary Prevention; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Time Factors | 2009 |
Fluoxetine inhibited extracellular matrix of pulmonary artery and inflammation of lungs in monocrotaline-treated rats.
Topics: Animals; Cytokines; Disease Models, Animal; Extracellular Matrix; Familial Primary Pulmonary Hypertension; Fluoxetine; Hypertension, Pulmonary; Inflammation; Lung; Male; Matrix Metalloproteinase Inhibitors; Monocrotaline; Pulmonary Artery; Rats; Rats, Wistar; Selective Serotonin Reuptake Inhibitors; Tissue Inhibitor of Metalloproteinases | 2011 |
Downregulation of osteopontin is associated with fluoxetine amelioration of monocrotaline-induced pulmonary inflammation and vascular remodelling.
Topics: Animals; Dose-Response Relationship, Drug; Down-Regulation; Fluoxetine; Inflammation; Lung; Lung Diseases; Monocrotaline; Osteopontin; Pulmonary Artery; Pulmonary Circulation; Rats; Rats, Inbred WF; Selective Serotonin Reuptake Inhibitors | 2011 |
Involvement of BMPR2 in the protective effect of fluoxetine against monocrotaline-induced endothelial apoptosis in rats.
Topics: Animals; Apoptosis; beta Catenin; Blood Pressure; Bone Morphogenetic Protein Receptors, Type II; Caspase 3; Cyclic GMP-Dependent Protein Kinases; Endothelial Cells; Fluoxetine; Gene Expression; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Lung; Male; Microvessels; Monocrotaline; Phosphorylation; Pulmonary Artery; Rats; Rats, Wistar; Smad1 Protein | 2011 |
Fluoxetine protects against monocrotaline-induced pulmonary arterial remodeling by inhibition of hypoxia-inducible factor-1α and vascular endothelial growth factor.
Topics: Animals; Antihypertensive Agents; Cell Proliferation; Disease Models, Animal; Fluoxetine; Hemodynamics; Hypertension, Pulmonary; Hypertrophy; Hypoxia-Inducible Factor 1, alpha Subunit; Lung; Male; MAP Kinase Signaling System; Monocrotaline; Myocytes, Smooth Muscle; Pulmonary Artery; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Vascular Endothelial Growth Factor A | 2012 |
Fluoxetine inhibits monocrotaline-induced pulmonary arterial remodeling involved in inhibition of RhoA-Rho kinase and Akt signalling pathways in rats.
Topics: Airway Remodeling; Animals; Disease Models, Animal; Down-Regulation; Familial Primary Pulmonary Hypertension; Fluoxetine; Hypertension, Pulmonary; Isoenzymes; Lung; Male; MAP Kinase Signaling System; Monocrotaline; Phosphorylation; Protein Processing, Post-Translational; Protein Transport; Proto-Oncogene Proteins c-akt; Pulmonary Artery; Random Allocation; Rats; Rats, Wistar; rho-Associated Kinases; rhoA GTP-Binding Protein; Selective Serotonin Reuptake Inhibitors | 2012 |
Rapamycin reverses pulmonary artery smooth muscle cell proliferation in pulmonary hypertension.
Topics: Animals; Apoptosis; Benzamides; Cell Proliferation; Cells, Cultured; Fluoxetine; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Hypertension, Pulmonary; Imatinib Mesylate; Male; Monocrotaline; Myocytes, Smooth Muscle; Phosphorylation; Piperazines; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Pulmonary Artery; Pyrimidines; Rats; Rats, Wistar; Ribosomal Protein S6 Kinases; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2013 |
Assessment of the serotonin pathway as a therapeutic target for pulmonary hypertension.
Topics: Acetylcholine; Angiography; Animals; Disease Models, Animal; Endothelium, Vascular; Fluoxetine; Humans; Hypertension, Pulmonary; Lung; Male; Molecular Targeted Therapy; Monocrotaline; Rats; Rats, Sprague-Dawley; Serotonin; Serotonin Plasma Membrane Transport Proteins; Vasodilation | 2013 |
Involvement of S100A4/Mts1 and associated proteins in the protective effect of fluoxetine against MCT - Induced pulmonary hypertension in rats.
Topics: Animals; Dose-Response Relationship, Drug; Fluoxetine; Hypertension, Pulmonary; Male; Monocrotaline; Proto-Oncogene Proteins c-mdm2; Rats; Rats, Wistar; Receptor for Advanced Glycation End Products; S100 Calcium-Binding Protein A4; Tumor Suppressor Protein p53 | 2018 |